Skip to main content
Premium Trial:

Request an Annual Quote

Just Say No

A special committee of Genentech's board asks the company's investors to reject Roche's hostile bid, reports the Wall Street Journal. Genentech says that the hostile Roche offer, at $86.50 a share, is "inadequate and not in the best interest of shareholders" and undervalues Genentech's financial outlook, its history of developing new medicines, and its product pipeline. Roche responded to the committee's recommendation by saying Roche has made its case and it is now up to the investors.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.